The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Strategies for developing sensitive and specific nanoparticle-based lateral flow assays as point-of-care diagnostic device
Abstract
Abstract From a home-based pregnancy self-testing kit, lateral flow assays (LFAs) have proliferated and gained widespread utilization as point-of-care (POC) test kits. Their prevalence is due to their portability, rapid time-to-result, simplicity, stability, and cost-effectiveness. LFAs are well-suited for early detection of infectious diseases, which threatens public health and the economy, enabling timely medical intervention, and management of disease and treatment. This is vital for rural and resource-limited settings where well-equipped laboratories with well-trained personnel are scarce. Nevertheless, LFAs have certain limitations, such as moderate sensitivity and target throughput, as compared to lab-based technologies. Also, the development of LFA, although well-defined, is not straightforward. In this review article, we will elucidate the iterative process of LFA development, and discuss strategies for generating sensitive and specific capture/detector agents, multiplexed detection and signal amplification. An important starting point in LFA development is the clear definition/identification of design inputs and predicate. Newly engineered capture/detector agents, such as nanobodies and aptamers, should possess high binding affinity and functionality in body fluid samples for practical field application. Also, chemical methods, combined with engineering, have enabled multiplexing and signal amplification capabilities for higher target throughput and detection sensitivity. Furthermore, LFAs can be augmented or adapted to other platforms, such as smartphone, spectroscopy and electrochemistry, for quantitative measurements that can engender wider applications and adoption. Through these advances, LFA will transform into a genuinely versatile platform, capable of delivering accurate results that are similar to lab-based technologies, while retaining its advantage as a simple, portable, inexpensive and rapid test.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanobodies: natural single-domain antibodies
Muyldermans, S. (2013) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-063011-092449 · Cited by 2,304
Reproducibility crisis: Blame it on the antibodies
Baker, M. (2015) · Nature · doi:10.1038/521274a · Cited by 830
Reproducibility: Standardize antibodies used in research
Bradbury, A., & Plückthun, A. (2015) · Nature · doi:10.1038/518027a · Cited by 647
Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology
Sattlecker, M., Kiddle, S. J., Newhouse, S., Proitsi, P., Nelson, S., Williams, S., Johnston, C., Killick, R., Simmons, A., Westman, E., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.09.016 · Cited by 223
Assay optimization for molecular detection of Zika virus
Corman, V., Rasche, A., Baronti, C., Aldabbagh, S., Cadar, D., Reusken, C., Pas, S., Goorhuis, A., Schinkel, J., Molenkamp, R., et al. (2016) · Bulletin of the World Health Organization · doi:10.2471/blt.16.175950 · Cited by 166
Cited by
COVID-19 diagnosis —A review of current methods
Yüce, M., Filiztekin, E., & Özkaya, K. G. (2021) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2020.112752 · Cited by 757
Ultrasensitive and Highly Specific Lateral Flow Assays for Point-of-Care Diagnosis
Liu, Y., Zhan, L., Qin, Z., Sackrison, J., & Bischof, J. C. (2021) · ACS Nano · doi:10.1021/acsnano.0c10035 · Cited by 626
Point-of-care diagnostics for infectious diseases: From methods to devices
Wang, C., Liu, M., Wang, Z., Li, S., Deng, Y., & He, N. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101092 · Cited by 622
Tutorial: design and fabrication of nanoparticle-based lateral-flow immunoassays
Parolo, C., Sena-Torralba, A., Bergua, J. F., Calucho, E., Fuentes-Chust, C., Hu, L., Rivas, L., Álvarez-Diduk, R., Nguyen, E. P., Cinti, S., et al. (2020) · Nature Protocols · doi:10.1038/s41596-020-0357-x · Cited by 576
Multifunctional mesoporous silica nanoparticles for biomedical applications
Xu, B., Li, S., Shi, R., & Liu, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01654-7 · Cited by 433
Metadata
- Authors
- Soh, J. H., Chan, H.-M., & Ying, J. Y.
- Venue
- Nano Today
- Publisher
- Elsevier BV
- Published
- 2020-02
- Volume
- 30
- Pages
- 100831
- ISSN
- 1748-0132 (ISSN-L)
- OpenAlex
- W2997668023
- Cited by
- 230
- References
- 5
- FWCI
- 9.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Strategies for developing sensitive and specific nanoparticle-based lateral flow assays as point-of-care diagnostic device. https://app.cochat.ai/papers/10.1016/j.nantod.2019.100831
- The paper
- Soh, J. H., Chan, H.-M., & Ying, J. Y. (2020). Strategies for developing sensitive and specific nanoparticle-based lateral flow assays as point-of-care diagnostic device. Nano Today. https://doi.org/10.1016/j.nantod.2019.100831
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.